176 related articles for article (PubMed ID: 37863019)
21. [New systemic antifungal drugs: mechanisms of action, drug interactions and side effects].
Schäfer-Korting M
Mycoses; 2003; 46 Suppl 1():28-31. PubMed ID: 12955850
[TBL] [Abstract][Full Text] [Related]
22. Antifungal drug resistance to azoles and polyenes.
Masiá Canuto M; Gutiérrez Rodero F
Lancet Infect Dis; 2002 Sep; 2(9):550-63. PubMed ID: 12206971
[TBL] [Abstract][Full Text] [Related]
23. Emerging Role of Sphingolipids in Amphotericin B Drug Resistance.
Madaan K; Bari VK
Microb Drug Resist; 2023 Aug; 29(8):319-332. PubMed ID: 37327022
[TBL] [Abstract][Full Text] [Related]
24. Overexpression or Deletion of Ergosterol Biosynthesis Genes Alters Doubling Time, Response to Stress Agents, and Drug Susceptibility in
Bhattacharya S; Esquivel BD; White TC
mBio; 2018 Jul; 9(4):. PubMed ID: 30042199
[TBL] [Abstract][Full Text] [Related]
25. The value of amphotericin B in the treatment of invasive fungal infections.
Klepser M
J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
[TBL] [Abstract][Full Text] [Related]
26. The effect of antifungal resistance development on the virulence of Candida species.
Bohner F; Papp C; Gácser A
FEMS Yeast Res; 2022 Apr; 22(1):. PubMed ID: 35325128
[TBL] [Abstract][Full Text] [Related]
27. Sterol uptake and sterol biosynthesis act coordinately to mediate antifungal resistance in Candida glabrata under azole and hypoxic stress.
Li QQ; Tsai HF; Mandal A; Walker BA; Noble JA; Fukuda Y; Bennett JE
Mol Med Rep; 2018 May; 17(5):6585-6597. PubMed ID: 29532896
[TBL] [Abstract][Full Text] [Related]
28. Effect of potassium ions at the different concentration on the interaction between AmB and the lipid monolayer containing cholesterol or ergosterol.
Wang J; Ma Y; Hou S
Biochem Biophys Res Commun; 2020 Jan; 521(3):699-705. PubMed ID: 31699370
[TBL] [Abstract][Full Text] [Related]
29. Antagonism of the Azoles to Olorofim and Cross-Resistance Are Governed by Linked Transcriptional Networks in Aspergillus fumigatus.
van Rhijn N; Hemmings S; Storer ISR; Valero C; Bin Shuraym H; Goldman GH; Gsaller F; Amich J; Bromley MJ
mBio; 2022 Dec; 13(6):e0221522. PubMed ID: 36286521
[TBL] [Abstract][Full Text] [Related]
30. New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species.
Silva LN; de Mello TP; de Souza Ramos L; Branquinha MH; Dos Santos ALS
Curr Top Med Chem; 2019; 19(28):2527-2553. PubMed ID: 31654512
[TBL] [Abstract][Full Text] [Related]
31. Systemic Antifungal Agents: Current Status and Projected Future Developments.
Seyedmousavi S; Rafati H; Ilkit M; Tolooe A; Hedayati MT; Verweij P
Methods Mol Biol; 2017; 1508():107-139. PubMed ID: 27837500
[TBL] [Abstract][Full Text] [Related]
32. Novel Approaches for Efficient Antifungal Drug Action.
Lee H; Lee DG
J Microbiol Biotechnol; 2018 Nov; 28(11):1771-1781. PubMed ID: 30178649
[TBL] [Abstract][Full Text] [Related]
33. Systemic antifungal agents. What is in the pipeline?
Kauffman CA
Drugs R D; 1999 Feb; 1(2):153-9. PubMed ID: 10566012
[TBL] [Abstract][Full Text] [Related]
34. Resistance of human fungal pathogens to antifungal drugs.
Sanglard D
Curr Opin Microbiol; 2002 Aug; 5(4):379-85. PubMed ID: 12160856
[TBL] [Abstract][Full Text] [Related]
35. Fungal vaccines.
Pattison HT; Millar BC; Moore JE
Br J Biomed Sci; 2021 Oct; 78(4):167-176. PubMed ID: 33751908
[TBL] [Abstract][Full Text] [Related]
36. The Future of Antifungal Drug Therapy: Novel Compounds and Targets.
Mota Fernandes C; Dasilva D; Haranahalli K; McCarthy JB; Mallamo J; Ojima I; Del Poeta M
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229427
[TBL] [Abstract][Full Text] [Related]
37. Drugs in Clinical Development for Fungal Infections.
Gonzalez-Lara MF; Sifuentes-Osornio J; Ostrosky-Zeichner L
Drugs; 2017 Sep; 77(14):1505-1518. PubMed ID: 28840541
[TBL] [Abstract][Full Text] [Related]
38. Antifungal drugs on the horizon.
Hay RJ
J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S82-6. PubMed ID: 8077515
[TBL] [Abstract][Full Text] [Related]
39. Sphingolipids as targets for treatment of fungal infections.
Rollin-Pinheiro R; Singh A; Barreto-Bergter E; Del Poeta M
Future Med Chem; 2016 Aug; 8(12):1469-84. PubMed ID: 27502288
[TBL] [Abstract][Full Text] [Related]
40. [Antifungals for systemic use].
Ruiz-Camps I; Cuenca-Estrella M
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):353-62. PubMed ID: 19482382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
